How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
Am Soc Clin Oncol Educ Book
; : 114-6, 2013.
Article
em En
| MEDLINE
| ID: mdl-23714473
ABSTRACT
Although the central role of 1p/19q codeletion in oligodendroglioma was established almost two decades ago, apart from clear prognostic significance the implications for clinical care have been less clear. This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma. These have shown that 1p/19q loss in these tumors is predictive of overall survival benefit of the addition of PCV chemotherapy to radiotherapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligodendroglioma
/
Radioterapia
/
Cromossomos Humanos Par 1
/
Cromossomos Humanos Par 19
/
Neoplasias Encefálicas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Deleção Cromossômica
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article